Ipsen bets up to $363M on an­oth­er shot at a de­bil­i­tat­ing con­di­tion re­lat­ed to Parkin­son's dis­ease

Ipsen is in a deal-mak­ing mood. On Thurs­day, the com­pa­ny put down $28 mil­lion up­front and an­oth­er $335 mil­lion in biobucks for the rights to IR­LAB’s mid-stage can­di­date for lev­odopa-in­duced dysk­i­ne­sia (LID) — a con­di­tion re­lat­ed to Parkin­son’s dis­ease that tripped up the French biotech about a decade ago.

“This is some­thing that fits nice­ly with our strat­e­gy in neu­ro­science, with move­ment dis­or­ders, and we’re al­so ob­vi­ous­ly look­ing more broad­ly in oth­er ther­a­peu­tic ar­eas, in our core ther­a­peu­tic ar­eas, in­clud­ing rare dis­eases and on­col­o­gy,” ex­ec­u­tive VP and head of R&D Howard May­er told End­points News. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER